Table 5.
Mid-diaphyseal femoral cortical bone parameters determined by dynamic bone histomorphometry of mice housed at normobaric ambient pressure (Normo) or hypobaric pressure (Hypo) at 500 mbar for four weeks and treated with acetazolamide (AZ) or zoledronate (ZOL). Periosteal bone surface (Ps), endocortical bone surface (Ec), mineralizing surface/bone surface (MS/BS), mineral apposition rate (MAR), and bone formation rate (BFR/BS).
| Normo | Hypo | Hypo + AZ | Hypo + ZOL | |
|---|---|---|---|---|
| Ps.MS/BS (%) | 19.3 ± 11.3 | 23.7 ± 17.5 | 13.3 ± 8.80 | 17.1 ± 9.53 |
| Ps.MAR (µm/day) | 0.18 ± 0.28 | 0.43 ± 0.45 | 0.30 ± 0.44 | 0.36 ± 0.43 |
| Ps.BFR/BS (µm3/µm2/day) | 0.04 ± 0.06 | 0.16 ± 0.18 | 0.06 ± 0.09 | 0.08 ± 0.10 |
| Ec.MS/BS (%) | 26.5 ± 6.98 | 29.6 ± 7.20 | 23.4 ± 9.30 | 15.3*,#,† ± 10.8 |
| Ec.MAR (µm/day) | 0.99 ± 0.78 | 1.17 ± 0.58 | 0.82 ± 0.65 | 0.45# ± 0.57 |
| Ec.BFR/BS (µm3/µm2/day) | 0.28 ± 0.24 | 0.35 ± 0.19 | 0.45 ± 0.57 | 0.11# ± 0.16 |
All data were analyzed using a one-way ANOVA, except for Ps.MAR and Ec.MAR where the non-parametric Kruskal–Wallis test was used. Data are presented as mean ± SD and n = 15–16/group. *p < 0.05 vs. Normo, #p < 0.05 vs. Hypo, and †p < 0.05 vs. Hypo + AZ.